These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 37210839)
1. Recent advances in the development of dual ALK/ROS1 inhibitors for non-small cell lung cancer therapy. Li Y; Lv Y; Zhang C; Fu B; Liu Y; Hu J Eur J Med Chem; 2023 Sep; 257():115477. PubMed ID: 37210839 [TBL] [Abstract][Full Text] [Related]
2. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer. Remon J; Pignataro D; Novello S; Passiglia F Cancer Treat Rev; 2021 Apr; 95():102178. PubMed ID: 33743408 [TBL] [Abstract][Full Text] [Related]
3. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors. Sgambato A; Casaluce F; Maione P; Gridelli C Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012 [TBL] [Abstract][Full Text] [Related]
4. Resistance Mechanisms to Targeted Therapies in McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358 [No Abstract] [Full Text] [Related]
5. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer. Zhang L; Jiang T; Li X; Wang Y; Zhao C; Zhao S; Xi L; Zhang S; Liu X; Jia Y; Yang H; Shi J; Su C; Ren S; Zhou C Cancer; 2017 Aug; 123(15):2927-2935. PubMed ID: 28346673 [TBL] [Abstract][Full Text] [Related]
6. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt. Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823 [TBL] [Abstract][Full Text] [Related]
7. Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer. Yang Y; Zheng Q; Wang X; Zhao S; Huang W; Jia L; Ma C; Liu S; Zhang Y; Xin Q; Sun Y; Zheng S Invest New Drugs; 2023 Apr; 41(2):254-266. PubMed ID: 37036582 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor. Lee J; Sun JM; Lee SH; Ahn JS; Park K; Choi Y; Ahn MJ Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630 [TBL] [Abstract][Full Text] [Related]
9. Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models. Fang DD; Tao R; Wang G; Li Y; Zhang K; Xu C; Zhai G; Wang Q; Wang J; Tang C; Min P; Xiong D; Chen J; Wang S; Yang D; Zhai Y BMC Cancer; 2022 Jul; 22(1):752. PubMed ID: 35820889 [TBL] [Abstract][Full Text] [Related]
10. MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF. Kondo N; Utsumi T; Shimizu Y; Takemoto A; Oh-Hara T; Uchibori K; Subat-Motoshi S; Ninomiya H; Takeuchi K; Nishio M; Miyazaki Y; Katayama R JCI Insight; 2023 Dec; 8(24):. PubMed ID: 37917191 [TBL] [Abstract][Full Text] [Related]
11. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers. Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242 [TBL] [Abstract][Full Text] [Related]
12. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age. Ke L; Xu M; Jiang X; Sun X Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372 [TBL] [Abstract][Full Text] [Related]
13. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples. Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206 [TBL] [Abstract][Full Text] [Related]
14. An updated patent review of small-molecule ROS1 kinase inhibitors (2015-2021). Liu M; Dai J; Wei M; Pan Q; Zhu W Expert Opin Ther Pat; 2022 Jun; 32(6):713-729. PubMed ID: 35343863 [TBL] [Abstract][Full Text] [Related]
15. MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling. Chen N; Tyler LC; Le AT; Welsh EA; Fang B; Elliott A; Davies KD; Danhorn T; Riely GJ; Ladanyi M; Haura EB; Doebele RC Mol Cancer Ther; 2024 Jan; 23(1):92-105. PubMed ID: 37748191 [TBL] [Abstract][Full Text] [Related]
16. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF. Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879 [TBL] [Abstract][Full Text] [Related]